Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 856 AL 870

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease

Ketron GL, Grun F, Grill JD, Feldman HH, Rissman RA, Brewer GJ.

Alzheimers Res Ther. 2025 Mar 11;17(1):59. doi: 10.1186/s13195-025-01693-y.

MicroRNA-based recent research developments in Alzheimer's disease

Ramirez-Gomez J, Dalal S, Devara D, Sharma B, Rodarte D, Kumar S.

J Alzheimers Dis. 2025 Mar;104(1):14-31. doi: 10.1177/13872877241313397. Epub 2025 Feb 2.

Tailoring the biomarkers of Alzheimer's disease using a gut microbiome-centric approach: Preclinical, clinical, and regulatory perspectives

Sharma S, Bashir B, Kolekar KA, Acharya A, Gupta M, Jena R, Vishwas S, Kaur J, Gupta G, Kumbhar PS, Patle D, Chaitanya M, Gulati M, Singh SK.

Ageing Res Rev. 2025 Dec;112:102888. doi: 10.1016/j.arr.2025.102888. Epub 2025 Sep 1.

The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer's Disease

Katsipis G, Tzekaki EE, Iasonidou S, Pantazaki AA.

Cells. 2025 Sep 11;14(18):1424. doi: 10.3390/cells14181424.

Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis

Wu S, Rajiah T, Ali AB.

Int J Mol Sci. 2025 Dec 11;26(24):11963. doi: 10.3390/ijms262411963.

New Research on Biomarkers in Alzheimer's Continuum

Vecchio I, Colica C.

Rev Recent Clin Trials. 2025;20(3):211-231. doi: 10.2174/0115748871331138250114052615.

Alzheimer's disease: assessing the therapeutic potential of anti-Aβ (Beta-Amyloid) treatments

Almutairi JA.

Cell Mol Biol (Noisy-le-grand). 2025 Feb 2;71(1):111-117. doi: 10.14715/cmb/2025.70.1.12.

The Role of Blood-Based Biomarkers in Transforming Alzheimer's Disease Research and Clinical Management: A Review

Pacoova Dal Maschio V, Roveta F, Bonino L, Boschi S, Rainero I, Rubino E.

Int J Mol Sci. 2025 Sep 3;26(17):8564. doi: 10.3390/ijms26178564.

Transthyretin as a therapeutic target: the future of disease-modifying therapies for Alzheimer's disease

Shaw S, Porel P, Aran KR.

Mol Biol Rep. 2025 Apr 8;52(1):370. doi: 10.1007/s11033-025-10485-4.

Atypical Alzheimer's dementia: Addressing the subtypes, epidemiology, atypical presentations, diagnostic biomarkers, and treatment updates

Vora N, Patel P, Marsool MDM, Marsool ADM, Sunasra R, Ladani P, Pati S, Khoont D, Prajjwal P, Ranjan R.

Dis Mon. 2025 May;71(5):101863. doi: 10.1016/j.disamonth.2025.101863. Epub 2025 Feb 1.

Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study

Wang S, Xi J, Zhang M, Wang J.

Int J Biol Macromol. 2025 Mar;294:139394. doi: 10.1016/j.ijbiomac.2024.139394. Epub 2025 Jan 3.

The challenging concept of preclinical Alzheimer's disease

Wallon D, Garnier-Crussard A.

Rev Neurol (Paris). 2025 Nov;181(9):881-892. doi: 10.1016/j.neurol.2025.07.016. Epub 2025 Nov 12.

The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility: Questions and Debates

Athanasaki A, Tsantzali I, Theodorou A, Michalopoulou A, Constantinides VC, Boufidou F, Tzartos JS, Tsalouchidou PE, Zompola C, Paraskevas SG, Bonakis A, Giannopoulos S, Tsivgoulis G, Kapaki E, Paraskevas GP.

Int J Mol Sci. 2025 Sep 29;26(19):9531. doi: 10.3390/ijms26199531.

The Inflammatory Nexus: Unraveling Shared Pathways and Promising Treatments in Alzheimer's Disease and Schizophrenia

Russo AP, Pastorello Y, Dénes L, Brînzaniuc K, Krupinski J, Slevin M.

Int J Mol Sci. 2025 Jun 27;26(13):6237. doi: 10.3390/ijms26136237.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias